Metallomics · 2011 · 138 citations · 33 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer MetabolismChemotherapy ResistanceMalignant NeoplasmsMetabolic ReprogrammingMetabolic Reprogramming In CancerMitochondrial ToxicologyCytotoxicity AssaysDna Oxidative AdductsMitochondrial Detoxification MechanismsOrganometallic Anticancer AgentsPlatinum CompoundsPlatinum SensitivityPlatinum-based AgentsTherapeutic Resistance Metabolism
The cellular uptake and subcellular distribution including adduct formation with genomic DNA and uptake into mitochondria of two ruthenium(iii)-based drugs in clinical trials, KP1019 and NAMI-A, and cisplatin, was investigated in cisplatin sensitive and resistant A2780 human ovarian carcinoma cells. These data indicate that reduced metal uptake into mitochondria in combination with increased binding towards low molecular weight components involved in detoxification mechanisms is essential for cisplatin resistance. The ruthenium drugs show distinct differences with respect to cisplatin, especially in the cisplatin resistant cells; in comparison to the sensitive cells, KP1019 exhibits higher cytotoxicity and an only slightly changed metabolism of the drug, whereas NAMI-A treatment results in increased intracellular ruthenium levels and a higher number of ruthenium-DNA adducts. In addition, size exclusion-inductively coupled mass spectrometry indicates that adduct formation with high molecular weight components in the particulate and nuclear fractions is crucial for the therapeutic effect of KP1019 in both cisplatin resistant and sensitive cell lines.
33
Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim et al. · Clinical Cancer Research · 2004 · 823 citations · Full text
Medicine, Oncology, Pharmacology +12
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
C. Scolaro, Alberta Bergamo, L. Brescacin et al. · Journal of Medicinal Chemistry · 2005 · 774 citations · Full text
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
Uta‐Maria Ohndorf, Mark A. Rould, Qing He et al. · Nature · 1999 · 562 citations